Cambrex reported a 14% increase in Q1 sales to $70.6m and EBITDA increased by 41% to $15.6m. The company attributed the increase in sales to higher volumes of controlled substances and generic APIs.
Cambrex
Tuesday, 8 May 2012
Cambrex Q1 sales rise
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment